Cardiome Announces Suspension of Enrollment in ACT 5 Trial

October 21, 2010
Cardiome Pharma Corp. Thursday announced that its co-development partner, Astellas Pharma US., Inc., has suspended patient enrollment in the ACT 5 study of Kynapid (vernakalant hydrochloride) Injection following a single unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received Kynapid.